| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2754273 | Clinical Lymphoma Myeloma and Leukemia | 2016 | 9 Pages |
Abstract
In a population of patients ineligible for high-dose therapy with autologous stem cell support, consolidation of response to chemoimmunotherapy with RIT was well tolerated and should be considered in patients with disease responsive to induction therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Patrick M. Reagan, Andrea Baran, Jennifer L. Kelly, Paul M. Barr, Carla Casulo, Vaseem U. Chengazi, Jonathan W. Friedberg,